Newron Pharmaceuticals S.p.A. header image

Newron Pharmaceuticals S.p.A.

NWRN

Equity

ISIN IT0004147952 / Valor 2791431

SIX Swiss Exchange (2024-11-21)

CHF 7.28+4.00%

Newron Pharmaceuticals S.p.A.
UMushroom community rating:

4.75 2 votes No rating yet

NegativeNeutralPositive

About company

Newron Pharmaceuticals S.p.A. is a biopharmaceutical company founded in 1999 and headquartered in Bresso, Italy, with a subsidiary in Morristown, USA. The company is focused on developing novel therapies for patients with diseases of the central and peripheral nervous system. Newron is listed on the SIX Swiss Exchange, the primary market of the Düsseldorf Stock Exchange, and on XETRA. The company is dedicated to expanding its portfolio of products through in-house efforts, as well as through licensing and acquiring novel CNS compounds at various stages of development.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results ():

Summarized from source with an LLMView Source

Key figures

50.4%1Y

293%3Y

5.66%5Y

Performance

77.5%1Y

83.4%3Y

95.5%5Y

Volatility

152 M

Market cap (USD)

52,159

Daily traded volume (Shares)

7.42 / 7

1 day high/low (USD)

0.00 / 0.00

52 weeks high/low (USD)

01 January, 2022

Dividend ex-date

0.00

Dividend (USD)

0.00%

Dividend yield (p.a.)

0.002022

0.002023

0.002024

Est dividend (USD)

0.00%2022

0.00%2023

0.00%2024

Est dividend yield

10.00

P/E ratio

00.002022

00.002023

00.002024

Est P/E ratio

0.00

EPS (USD)

0.002022

0.002023

0.002024

Est EPS (USD)

Ratings & reviews

4.75

2 votes

Performance:

3.00

Innovation:

4.75

Society:

4.75

Nature:

4.50

Markus Fässler

Switzerland, 05 Feb 2024

Evenamide, Newron’s innovative drug to treat schizophrenia, has proven safe and effective in use for TRS patients.

Luba Schoenig

Switzerland, 07 Jan 2023

EQUITIES OF THE SAME SECTOR

Evotec SE

Evotec SE Valor: 505433

Annual Return

-50%0%+50%

Risk level

110

1.67%EUR 10.07

Dermapharm Holding SE

Dermapharm Holding SE Valor: 40166352

Annual Return

-50%0%+50%

Risk level

110

1.63%EUR 37.50

Amicus Therapeutics Inc

Amicus Therapeutics Inc Valor: 2644388

Annual Return

-50%0%+50%

Risk level

110

-0.94%USD 9.50

CHAPTERS Group AG

CHAPTERS Group AG Valor: 2175722

Annual Return

-50%0%+50%

Risk level

110

-2.54%EUR 23.00

Geratherm Medical AG

Geratherm Medical AG Valor: 1091371

Annual Return

-50%0%+50%

Risk level

110

2.24%EUR 2.74

National Vision Holdings Inc

National Vision Holdings Inc Valor: 38523646

Annual Return

-50%0%+50%

Risk level

110

1.85%USD 11.55

Arjo AB

Arjo AB Valor: 39115843

Annual Return

-50%0%+50%

Risk level

110

-0.55%SEK 32.84

Biogaia AB

Biogaia AB Valor: 118922125

Annual Return

-50%0%+50%

Risk level

110

0.67%SEK 104.70

Johnson & Johnson

Johnson & Johnson Valor: 943981

Annual Return

-50%0%+50%

Risk level

110

1.56%USD 155.50

Novo Nordisk A/S

Novo Nordisk A/S Valor: 461641

Annual Return

-50%0%+50%

Risk level

110

-2.51%USD 102.63

SIX

FactSet

Clearbit

Logos provided by Clearbit